MWNA
THRN

Marshall Wace North America’s Thorne Healthtech, Inc. Common Stock THRN Stock Holding History

Marshall Wace North America’s Portfolio THRN Stock Details THRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$268K Buy
+30,993
New +$253K ﹤0.01% 1275

Other funds holding THRN

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
Teacher Retirement System of Texas
Teacher Retirement System of Texas Austin, Texas $24B AUM 29.51% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
SI
Scout Investments Kansas City, Missouri $3.8B AUM 45.91% 1-Year Est. Return

Marshall Wace North America's THRN Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Thorne Healthtech, Inc. Common Stock (THRN) in Q3 2021: 30,993 shares worth $268K. The stake represents ﹤0.01% of the portfolio and ranks #1275 among its holdings.

41 funds tracked by Wall St. Rank hold THRN as of Q3 2021.

  • Marshall Wace North America held 30,993 shares of Thorne Healthtech, Inc. Common Stock worth $268K as of Q3 2021.
  • Thorne Healthtech, Inc. Common Stock was a new Marshall Wace North America position in Q3 2021.
  • Thorne Healthtech, Inc. Common Stock made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1275 holding.
  • 41 funds tracked by Wall St. Rank held Thorne Healthtech, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.